HBHilde M. H. Braakman

Hilde M. H. Braakman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hilde M. H. Braakman has a total of 350 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring the gut microbiome in children and young adults with myotonic dystrophy type 1

    by Anne M. van Uden, Heidi Zweers, Alejandro Arias Vasquez, Derick G. Wansink, Peter A. C. ’T Hoen, Alem Gusinac, Anja de Baaij-Daalmeyer, Karlijn Gerrits, Willem J. G. Melchers, Baziel van Engelen, et al.

    Myotonic Dystrophy type 1 (DM1) is a complex multisystem disorder, and affected children commonly present with gastrointestinal and neurodevelopmental challenges. Despite the high prevalence of these symptoms, their underlying mechanisms remain poorly understood. The gut microbiome is known to be involved in gastrointestinal and neurodevelopmental disorders, and emerging research suggests that it could also play a contributory role in various neuromuscular diseases. However, the gut microbiota of children with DM1 remains unexplored. This pilot study compared gut microbiota profiles of 10 children and one young adult with DM1, to that of their unaffected siblings (n=11). Three-day food records and faecal samples were collected, and bacterial taxa were analysed through 16S rRNA marker-gene sequencing. A within-family paired-sample design accounted for potential confounders, such as diet and lifestyle. Results revealed that overall microbial diversity and community structure were similar between groups. Moreover, participants with DM1 showed a significant lower relative abundance of the bacterial genus Faecalibacterium (mean 4.9% ± 2.1%) compared to their unaffected siblings (mean 9.1% ± 4.4%)(p=0.005). This finding should be considered exploratory, as its univariate analysis was uncorrected for multiple testing. Faecalibacterium is a key gut bacterium, and reduced abundance has been reported in several DM1-associated gastrointestinal and neurodevelopmental disorders. Although causality cannot be inferred from this exploratory study the observed reduction may be relevant to gastrointestinal and neurodevelopmental challenges frequently seen in DM1. If larger further studies confirm its role, targeting Faecalibacterium relative abundance could become a potential therapeutic strategy for alleviating gastrointestinal and neurodevelopmental symptoms in DM1.

  • Open Access

    Further delineation of the SCAF4-associated neurodevelopmental disorder

    by Cosima M. Schmid, Anne Gregor, Anna Ruiz, Carmen Manso Bazús, Isabella Herman, Farah Ammouri, Urania Kotzaeridou, Vanda McNiven, Lucie Dupuis, Katharina Steindl, et al.

    While mostly de novo truncating variants in SCAF4 were recently identified in 18 individuals with variable neurodevelopmental phenotypes, knowledge on the molecular and clinical spectrum is still limited. We assembled data on 50 novel individuals with SCAF4 variants ascertained via GeneMatcher and personal communication. With detailed evaluation of clinical data, in silico predictions and structural modeling, we further characterized the molecular and clinical spectrum of the autosomal dominant SCAF4-associated neurodevelopmental disorder. The molecular spectrum comprises 25 truncating, eight splice-site and five missense variants. While all other truncating variants were classified as pathogenic/likely pathogenic, significance of one C-terminal truncating variant, one splice-site variant and the missense variants remained unclear. Three missense variants in the CTD-interacting domain of SCAF4 were predicted to destabilize the domain. Twenty-three variants occurred de novo, and variants were inherited in 13 cases. Frequent clinical findings were mild developmental delay with speech impairment, seizures, and skeletal abnormalities such as clubfoot, scoliosis or hip dysplasia. Cognitive abilities ranged from normal IQ to severe intellectual disability (ID), with borderline to mild ID in the majority of individuals. Our study confirms the role of SCAF4 variants in neurodevelopmental disorders and further delineates the associated clinical phenotype.


  • Open Access

    Electro‐Clinical Features and Functional Connectivity Analysis in SYN1‐Related Epilepsy

    by Vincent Moya Quiros, Ahmed Adham, Philippe Convers, Gaetan Lesca, François Mauguiere, Hugo Soulier, Alexis Arzimanoglou, Allan Bayat, Hilde Braakman, Jean‐Philippe Camdessanche, et al.

    Objective: There is currently scarce data on the electroclinical characteristics of epilepsy associated with synapsin 1 (SYN1) pathogenic variations. We examined clinical and electro‐encephalographic (EEG) features in patients with epilepsy and SYN1 variants, with the aim of identifying a distinctive electroclinical pattern.Methods: In this retrospective multicenter study, we collected and reviewed demographic, genetic, and epilepsy data of 19 male patients with SYN1 variants. Specifically, we analyzed interictal EEG data for all patients, and electro‐clinical data from 10 epileptic seizures in 5 patients, using prolonged video‐EEG monitoring recordings. Inter‐ictal EEG functional connectivity parameters and frequency spectrum of the 10 patients over 12 years of age, were computed and compared with those of 56 age‐ and sex‐matched controls.Results: The main electroclinical features of epilepsy in patients with SYN1 were (1) EEG background and organization mainly normal; (2) interictal abnormalities are often rare or not visible on EEG; (3) more than 60% of patients had reflex seizures (cutaneous contact with water and defecation being the main triggers) isolated or associated with spontaneous seizures; (4) electro‐clinical semiology of seizures was mainly temporal or temporo‐insulo/perisylvian with a notable autonomic component; and (5) ictal EEG showed a characteristic rhythmic theta/delta activity predominating in temporo‐perisylvian regions at the beginning of most seizures. Comparing patients with SYN1 to healthy subjects, we observed a shift to lower frequency bands in power spectrum of interictal EEG and an increased connectivity in both temporal regions.Interpretation: A distinct epilepsy syndrome emerges in patients with SYN1, with a rather characteristic clinical and EEG pattern suggesting predominant temporo‐insular involvement. ANN NEUROL 2025;97:34–50

  • Open Access

    Respiratory insufficiency as a presenting symptom of congenital myasthenic syndromes

    by Fleur van Den Udenhout, Peter Merkus, Sandra Verhaagen-Van Den Akker, Meyke Schouten, Corrie Erasmus, Hilde Braakman

    Respiratory insufficiency can be a presenting symptom of Congenital Myasthenic Syndromes (CMS) but is rarely recognized as such. CMS result from failure of the neuromuscular transmission secondary to gene mutations affecting the neuromuscular junction structure and function. A core symptom is muscle weakness that worsens with physical exertion. We describe five children who experienced severe to life threatening episodes of respiratory insufficiency, especially during viral infections, due to respiratory muscle weakness. During infections they often also had progression of their ocular, facial, and limb muscle weakness. All children were eventually diagnosed with genetically proven CMS. In all five children, treatment with pyridostigmine, an acetylcholinesterase inhibitor, resulted in clinical improvement. CMS should be considered in every patient with unexplained recurrent respiratory insufficiency, or with a disproportionate and unusually severe course of a (viral) respiratory infection. Early diagnosis of CMS is crucial for early treatment, which may help avoiding further deterioration of the muscle strength, severe respiratory insufficiency and sudden infant death.

  • Open Access

    Impact of gastrointestinal and urological symptoms in children with myotonic dystrophy type 1

    by Sandra J.M. Maagdenberg, Sylvia Klinkenberg, J. Sophie van Den Berg, Sandra Altena-Rensen, Desiree Vrijens, Etienne J.M. Janssen, Nicole Gierenz, Liesbeth L. de Wall, Hilde M.H. Braakman


  • Natural History and Developmental Trajectories of Individuals With Disease-Causing Variants in STXBP1

    by Kim M. Thalwitzer, Jan H. Driedger, Julie Xian, Afshin Saffari, Pia Zacher, Bigna K. Bölsterli, Sarah McKeown Ruggiero, Katie Rose Sullivan, Alexandre N. Datta, Christoph Kellinghaus, et al.

    Background and Objectives: Pathogenic variants in STXBP1 are among the major genetic causes of neurodevelopmental disorders. Despite the increasing number of individuals diagnosed without a history of epilepsy, little is known about the natural history and developmental trajectories in this subgroup and endpoints for future therapeutic studies are limited to seizure control. Methods: We performed a cross-sectional retrospective study using standardized questionnaires for clinicians and caregivers of individuals with STXBP1-related disorders capturing medical histories, genetic findings, and developmental outcomes. Motor and language function were assessed using Gross Motor Function Classification System scores (GMFCS) and a speech impairment score and were compared within and across clinically defined subgroups. Results: We collected data of 71 individuals with STXBP1-related disorders, including 44 previously unreported individuals. Median age at inclusion was 5.3 years (IQR = 3.5-9.3) with the oldest individual aged 43.8 years. Epilepsy was absent in 18/71 (25%) of individuals. The range of developmental outcomes was broad, including two individuals presenting with close to age-appropriate motor development. 29/61 (48%) individuals were able to walk unassisted and 24/69 (35%) were able to speak single words. Individuals without epilepsy presented with a similar onset and spectrum of phenotypic features but had lower GMFCS scores (median 3 vs. 4, p < 0.01) than individuals with epilepsy. Individuals with epileptic spasms were less likely to walk unassisted than individuals with other seizure types (6% vs. 58%, p < 0.01). Individuals with early epilepsy onset had higher speech impairment scores (p = 0.02) than individuals with later epilepsy onset. Discussion: We expand the spectrum of STXBP1-related disorders and provide clinical features and developmental trajectories in individuals with and without a history of epilepsy. Individuals with epilepsy, in particular epileptic spasms, and neonatal or early-onset, presented with less favorable motor and language functional outcomes compared to individuals without epilepsy. These findings identify children at risk for severe disease and can serve as comparator for future interventional studies in STXBP1-related disorders.


  • Open Access

    Recognising symptoms of congenital myasthenic syndromes in children: A guide for paediatricians

    by Lynn B. Orriëns, Dilan Eker, Hilde M. H. Braakman, Peter J. F. M. Merkus, Corrie E. Erasmus

    Aim: Congenital myasthenic syndromes (CMS) are a rare and diverse group of treatable neuromuscular transmission disorders. Diagnosis is often substantially delayed. This study aimed to identify common symptoms of CMS in children and their manifestation to aid diagnosis and early intervention.Methods: We performed a retrospective cohort study, including 18 children (median age 13 years, range 9 years 5 months-18 years 0 month) with CMS. Data on CMS symptoms and their manifestation were extracted from patients' charts and supplemented with parental telephone interviews. Descriptive analyses were used to identify common symptoms.Results: A median diagnostic delay of 4 years and 7 months (interquartile range: 51 months) was observed. Proximal muscle weakness (100%), ptosis (89%), clumsy gait (82%), difficulty eating solid foods (78%) and recurrent respiratory tract infections (72%) were most common in these patients. Symptoms mostly co-occurred and frequently had a fluctuating character, aggravated by infections or fatigue.Conclusion: Early referral to diagnose CMS is crucial to enable timely initiation of treatment. Heightened attention to a combination of symptoms related to muscle weakness, rather than individual symptoms, should support paediatricians in flagging these neuromuscular disorders. Medical history taking should be tailored to parents' perceptions, asking questions about recognisable symptoms of muscle weakness.


  • Open Access

    Pediatric acute flaccid myelitis: Evaluation of diagnostic criteria and differentiation from other causes of acute flaccid paralysis

    by Jelte Helfferich, Rinze F. Neuteboom, Marit M.A. de Lange, Kimberley S.M. Benschop, Coretta C. Van Leer-Buter, Adam Meijer, Dewi P. Bakker, Eva de Bie, Hilde M.H. Braakman, Rick Brandsma, et al.


  • Open Access

    Respiratory insufficiency as a presenting symptom of congenital myasthenic syndromes

    by Fleur van Den Udenhout, Peter Merkus, Sandra Verhaagen‐Van Den Akker, Meyke Schouten, Corrie Erasmus, Hilde Braakman

    Aim: Respiratory insufficiency can be a presenting symptom of congenital myasthenic syndromes (CMS) but is rarely recognised as such. In this study, we aim to raise awareness of CMS to paediatricians.Methods: We performed a retrospective case study of infants and preschool children treated in the past 5 years in Amalia Children's Hospital, Radboud University Medical Center in Nijmegen, the Netherlands for respiratory insufficiency as presenting symptom of CMS.Results: Five children aged 2 weeks to 5 years experienced severe to life‐threatening episodes of respiratory insufficiency, especially during viral infections, due to respiratory muscle weakness. During infections, they often also had progression of their otherwise mild ocular, facial, and limb muscle weakness. They were eventually diagnosed with genetically proven CMS. In these five children, treatment with pyridostigmine, an acetylcholinesterase inhibitor, resulted in clinical improvement.Conclusion: CMS should be considered in every patient with unexplained recurrent respiratory insufficiency, or with an unusually severe course of a normally mild respiratory infection, especially in combination with mild muscle weakness outside periods of illness. Early diagnosis of CMS is crucial for early treatment, which may help avoiding sudden infant death, severe respiratory insufficiency and further deterioration of the muscle strength.